CHAPTER-I - Amoebiasis - an Introduction INTRODUCTION

Total Page:16

File Type:pdf, Size:1020Kb

CHAPTER-I - Amoebiasis - an Introduction INTRODUCTION CHAPTER-I - Amoebiasis - An Introduction INTRODUCTION 1.1. The term amoebiasis denotes the condition of harbouring B,histolytica with or without clinical manifestations (WHO, 1969). The aetiological agent of amoebiasis is Entamoeba histolytica. 1,2• Epidemiology Amoebiasis has been reported practically from all over the world and has been estimated to affect 10% of the world population although its prevalence and severity may differ from area to area (WHO, 1969). Thus, it is a public health problem of International importance. In India, the prevalence of amoebiasis varies from 1-58% (Arora et al., 1977) . The highest prevalence rate among the asyrrptomatic people has been recorded to be 47,4% (Greval, 1968), and that in symptomatic patients 58% (Patel/ 1945). Prevalence rates of this disease in the states of Himachal Pradesh, Jammu and Kashmir, Orissa and Sikkim have been reported to be less than 10%. Prevalence rate ranging from 1-20% have been reported from Assam, Delhi, Gujarat and Madhya Pradesh. The states of Andhra Pradesh, Kerela, Rajasthan, U.P. and West Bengal showed prevalence rates upto 30% while in Maharashtra, Tamil Nadu and Chandigarh the rates were more than 30% (Arora et al., 1977). Although E.histolytica is generally more prevalent in the tropics and subtropics. the higher temperature and humidity are not thought to be directly responsible since the higher temperatures are likely to have an adverse effect on cysts in the environment. The increased prevalence in tropical countries is generally considered to reflect poor sanitation and health education rather than climatic conditions. Prevalence of E,histolytica is associated with unsanitary conditions in temperate and even in arctic regions (WHO, 1969). The unhygeinic working and living conditions, insanitary surroundings, improper handling of food, contami­ nation of food by cockroaches and flies and refervoir or hosts such as dogs, cats etc. (which are natural hosts of E,histolytica) play a very important role in the spread of the disease. Water, food and vegetables are potential carriers of thd disease. 1,3. Classification Kingdom - Protista Subkingdom - Protozoa Phylum - Sarcomastigophora Subphylxim - Sarcodina Superclass - Rhizopoda Class - Lobosa Subclass - Gymnamoebia Order - Amoebida 3 Suborder - Tubulina Family - Entamoebidae Genus and - Entamoeba histolytica species (Schaudinn, 1903). Of the seven species of amoebae which are natural parasites of man, only E.histolytica is truely pathogenic. Of current special interest is the recently discovered fact that free living amoebae of the genus Acanthamoeba (Synonym Harmane11a; Page, 1976) and Naegleria are facultative parasites of man and may be highly pathogenic when invading the meninges and brain via the nasal cavity (Singh, 1975) 1.4. Life cycle The life cycle of E»histolytica involves the, encystment of a trophozoite, followed by release of the tropho­ zoite from the cyst when the conditions are appropriate. The trophozoite undergoes encystment only within the bowel, usually associated with conditions in the lumen which are not ideal for continued activity of the trophozoite. The young cyst is uninuclear and it contains one large glycogen vacuole and chromatoid body. It is the non motile resting stage. It is round or oval measuring 2,5 to 3,5 p in diameter. The cyst matures either within the lumen of the bowel or outside the body in appropriately moist surroundings. The mature cyst contains four nuclei (the result of 2 nuclear divisions) and a number of chromatoid 4' bodies. When this cyst is ingested, another nuclear division occurs during the cyst 's transit through the small intestine and the resulting eight trophozoites escape through a hole created in the wall of the cyst. Trophozoites migrate to the colon where they persist, undergoing binary fission every eight hours in the trophozoite stage. Encystment of these organisms occur again when the trophozoites are excreted outside the body and environmental conditions not so favour­ able to continued trophozoite multiplication, the life cycle is complete (Wilcocks et al., 1971). The trophozoites are facultative anaerobes which require complex media for growth. The environment for optimum growth of amoeba in the colon includes a pH 6.0-6.5, a low redox potential, nutrients occuringi found in the colon particularly carbohydrates and the presence of bacteria. The trophozoite is the vegetative, motile stage measuring frcan 15-40 u. This stage is not responsible fot the spread of the disease since it is rapidly destroyed by the gastric pH and enzymes. The encysted stage readily passes this barrier. Cysts may remain viable for weeks or months in appropriate moist surroundings. The cyst, therefore, is the primary reason for the extensive prevalence of the infection throughout the world. The conditions that allow the amoebae to become invasive are not clear, however, virulence has been promoted in experimental animals by irritating the bowel with abrasives, chemicals or invasive bacteria (Lesh (Losch) 1975, Wittner et ^., l97o) . Trophozoites have been shovm to breakdown cement substance between epithelial cells of the intestine and to gain access to the submucosal region by moving between these cells (Tekeuchi et al., 1975). The events that trigger this process are not known but a number of factors in the host will contribute to Invasion such as high cholesterol, low ascorbic acid diet, high carbohydrate, low protein diet, the absence of previous exposure to amoebae, as well as climatic, emotional and genetic factors (Perez - Tamayo et al., 1971). 1,5. History Losch in 1875 discovered motile amoeba with ingested red blood cells in the dysenteric stools of a patient. Later at the autopsy of the patients he detected colonic ulcers containing active amoebae. He is credited with documenting amoeba to be pathogenic by inducing lesions in a dog with dysenteric stool. He named the protozoan Amoeba coli; but he did not regard the organism as the actual cause of the disease. After the discovery of Losch, discussion arose as to whether the amoeba was the aetiological agent of dysentery and this question remained unanswered for a long time. Kartulis, in Egypt in 1886, settled the role of amoeba as a fe cause of intestinal and hepatic lesions in patients with diarrhoea. Koch and Gaffky (1887) and Osier (1890) confinned the findings. Councilman and Lafleur (1891) published a complete study of 15 cases of amoebic dysentery. They named the parasite Amoeba dysenteriae. In 1893, Quincke and Roos demonstrated that cats could be infected either by feeding them with stool containing cysts or by injecting stool containing cysts, per anum. They distinguished amoebae other than "Amoeba coli Losch" by their lack of pathogenicity in cats. These they called "Amoeba coli mitis", found in mild dysentery; and "Amoeba intestinl vulgaris" found in the stools of healthy people. Casagrandi and Barbagallo (1897) described Entamoeba coli from healthy people, thus establishing the generic name Entamoeba as distinct from Endamoeba Leidy, 1897. Strong and Musgrave (1900) differentiated the pathogenic amoeba from non pathogenic one in the human intestine, They observed that in cats typical ulcers were produced by pathogenic amoeba, whereas a non-pathogenic amoeba produced no such lesions in these animals. Hxiber (1903) demonstrated quadrinucleate cysts, but thought that it was a different species other than Entamoeba coli, so he called it Entamoeba tetraqena. Schaudinn (1903) distinguished non pathogenic E.colJ. and the pathogenic haenratophagous E.histolytica. The name 'tetragena ' caused confusion. The concept that the quadranucleate cysts were those of some species other than S.histolytica remained imquestioned for a dozen years. Huber (1909), Hartmann (1908) and others accepted that E.tetragena was a separate species. Viereck (1907) stated that E.tetragena was a strain of E.cqli. Elmassian (1909) gave the name E.minuta for the trophozoites associated with quadranucleated cysts. Craig (1905) considered that the correct title should be B.dysenteriae. Thus in 1910, there were 4 names dysenteriae, tetragena, minuta and histolytica, for what is now considered to be a single entity. The accepted name for the parasite is Entamoeba histolytica (Schaudinn, 1903). Walker and Sellards (1913) demonstrated conclusively that man could be infected with the cysts of E.histolytica. In human volunteers fed with E.coli cysts, no such disease developed; thus it was shown experimentally for the first time, in man that E.histolytica was pathogenic to man. 1.6. Pathogenesis and pathology Commensal trophozoites thrive adjacent to the colonic mucosa where the oxygen tension is moderately low and the pH is between 6.0 and 6.5. Host tissue appears to be damaged only by direct contact with amoebae; lyso-somal enzymes are 8 released, possibly by activating a contact-sensitive surface organelle. The relatively anaerobic and acid conditions of cell necrosis favour further penetration of amoebae into the tissue. The role of intestinal bacteria^ in pathogenesis is still uncertain. They may act mainly by creating suitable conditions for the growth of amoebae. 1.6.1, Amoebic ulceration It is most common in the caecxim and rectosigmoid region, but may affect any part of the large intestine, appendix and terminal ileum. The initial lesions are small, discrete, superficial mucosal erosions which may then extend more deeply through the muscularis mucosae and spread lateraly, producing ulcers that are flasTc-shaped in cross
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Pharmaceutical Drug Analysis
    This page intentionally left blank Copyright © 2005, 2001, New Age International (P) Ltd., Publishers Published by New Age International (P) Ltd., Publishers All rights reserved. No part of this ebook may be reproduced in any form, by photostat, microfilm, xerography, or any other means, or incorporated into any information retrieval system, electronic or mechanical, without the written permission of the publisher. All inquiries should be emailed to [email protected] ISBN (13) : 978-81-224-2718-9 PUBLISHING FOR ONE WORLD NEW AGE INTERNATIONAL (P) LIMITED, PUBLISHERS 4835/24, Ansari Road, Daryaganj, New Delhi - 110002 Visit us at www.newagepublishers.com “Every Scientific Advance is an Advance in Method. The Invention of a New Specialized Laboratory Procedure Brings About Rapid Conquests in New Fields of Science and Technology. Finally, it Exhausts Itself and is Replaced by a Still More Practical Method” L. Zechmeister and L. Von Cholnoky This page intentionally left blank Preface to the Second Edition Modern Pharmaceutical Drug Analysis essentially involves as a necessary integral component even greater horizons than the actual prevalent critical analysis of not only the active pharmaceutical substances but also the secondary pharmaceutical product(s) i.e., the dosage forms having either single or multi-component formulated product. The fundamental reasons for this sudden legitimate surge in the newer evolving methodologies in the ‘analysis of drug substances’ are perhaps due to the tremendous growth in the progress of ‘medicinal chemistry’ towards achieving one ultimate objective which is to obtain ‘better drugs for a better world’. With the advent of computer-aided-drug modeling (CADM) the critical, scientific and faster approach to newer drug entities based on the biologically active prototypes, combinatorial chemis- try, chiral chemistry and biotechnology has paved the way towards more specific, potent and above all less toxic ‘drugs’ to improve the ultimate quality of life in humans.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • WO 2016/033635 Al 10 March 2016 (10.03.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/033635 Al 10 March 2016 (10.03.2016) P O P C T (51) International Patent Classification: AN, Martine; Epichem Pty Ltd, Murdoch University Cam Λ 61Κ 31/155 (2006.01) C07D 249/14 (2006.01) pus, 70 South Street, Murdoch, Western Australia 6150 A61K 31/4045 (2006.01) C07D 407/12 (2006.01) (AU). ABRAHAM, Rebecca; School of Animal and A61K 31/4192 (2006.01) C07D 403/12 (2006.01) Veterinary Science, The University of Adelaide, Adelaide, A61K 31/341 (2006.01) C07D 409/12 (2006.01) South Australia 5005 (AU). A61K 31/381 (2006.01) C07D 401/12 (2006.01) (74) Agent: WRAYS; Groud Floor, 56 Ord Street, West Perth, A61K 31/498 (2006.01) C07D 241/20 (2006.01) Western Australia 6005 (AU). A61K 31/44 (2006.01) C07C 211/27 (2006.01) A61K 31/137 (2006.01) C07C 275/68 (2006.01) (81) Designated States (unless otherwise indicated, for every C07C 279/02 (2006.01) C07C 251/24 (2006.01) kind of national protection available): AE, AG, AL, AM, C07C 241/04 (2006.01) A61P 33/02 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07C 281/08 (2006.01) A61P 33/04 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07C 337/08 (2006.01) A61P 33/06 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07C 281/18 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/AU20 15/000527 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (22) International Filing Date: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 28 August 2015 (28.08.2015) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Final1-Aritmo-Final-Report-V2-0Final.Pdf
    ARITMO Final Report PROJECT FINAL REPORT Grant Agreement number: 241679 Project acronym: ARITMO Project title: Arrhythmogenic potential of drugs Funding Scheme: Small or Medium-Scale Focused Research Project Period covered: from 1st January 2010 to 30th June 2013 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Miriam CJM Sturkenboom, Erasmus Universitair Medisch Centrum Rotterdam Tel: +31 10 704 4126 Fax: +31 10 704 4722 E-mail: [email protected] Project website1 address: www.aritmo-project.org 1 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm ; logo of the 7th FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned. © Copyright 2013 ARITMO Consortium 1 ARITMO Final Report Table of contents Table of contents ................................................................................................................................................................. 2 1. Final publishable summary report ................................................................................................................................ 3 1.1 Executive summary ................................................................................................................................................. 3 1.2 Description of project context and
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION November 2020 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems. The aim of harmonisation is to reach a “full” agreement of all mono substances in a given class as listed in the WHO ATC Index, mainly at third level: whenever this is not possible, or harmonisation of third level is too difficult or makes no sense (e.g.
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • PDF (Guidelines for ATC Classification and DDD Assignment)
    Guidelines for ATC classification and DDD assignment 2018 ISSN 1726-4898 ISBN 978-82-8082-896-5 Suggested citation: WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2018. Oslo, Norway, 2017. © Copyright WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. Guidelines for ATC classification and DDD assignment 21st edition WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health P.O.Box 4404 Nydalen N-0403 Oslo Norway Telephone: (47) 21078160 E-mail: [email protected] Website: www.whocc.no Previous editions: 1990: Guidelines for ATC classification1) 1991: Guidelines for DDD1) 1993: Guidelines for ATC classification 1993: Guidelines for DDD 1996: Guidelines for ATC classification and DDD assignment 1998: Guidelines for ATC classification and DDD assignment 2000: Guidelines for ATC classification and DDD assignment 2001: Guidelines for ATC classification and DDD assignment 2002: Guidelines for ATC classification and DDD assignment 2003: Guidelines for ATC classification and DDD assignment 2004: Guidelines for ATC classification and DDD assignment 2005: Guidelines for ATC classification and DDD assignment 2006: Guidelines for ATC classification and DDD assignment 2007: Guidelines for ATC classification
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]